Asset profile

Piribedil (Clarium)

Small molecule

Phase 3D2/D3No recent registered activity
Preview Research free. Sign in to unlock 3 full asset or company pages every day, no card needed.Sign in to unlock this page
Dormantno recent development

Evidence outlook

No registered development activity since 2012

Registered studies concluded by 2012, with no approval on record and no active or planned study on the registry since. No sponsor statement of discontinuation has been sourced, but the trial history should be read as archival rather than an active program.

How the evidence outlook works ↗

Competitive landscape

61 competitors in this universe: 1 direct rival (same mechanism and indication), 0 same-class, 60 same-indication; 18 further along in development.

Unlock with Research ↗
DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Piribedil (Clarium): this drugPhase 3Small moleculeD2/D3
Matsupexole (KDT-3594)Phase 2Small moleculeD2/D3
Amantadine ER (Gocovri / ADS-5102)ApprovedSmall moleculeNMDA receptor
Apomorphine (Apokyn)ApprovedSmall moleculedopamine
Apomorphine Sublingual Film (Kynmobi)ApprovedSmall moleculedopamine
Crexont (IPX203)ApprovedSmall moleculedopamine precursor
Entacapone (Comtess)ApprovedSmall moleculeCOMT
Foslevodopa / Foscarbidopa (Vyalev)ApprovedSmall moleculedopamine precursor
Inbrija (CVT-301)ApprovedSmall moleculedopamine precursor
Istradefylline (Nourianz)ApprovedSmall moleculeadenosine A2A
Levodopa-Carbidopa Intestinal Gel (Duopa)ApprovedSmall moleculedopamine precursor
Opicapone (Ongentys)ApprovedSmall moleculeCOMT, PDE4
ParcopaApprovedSmall moleculedopamine precursor
Pimavanserin (Nuplazid)ApprovedSmall molecule5-HT2A/2C receptor, Serotonin 5-HT2A receptor (antagonist / inverse agonist)
Pramipexole (Sifrol/Mirapex)ApprovedSmall moleculeDopamine D2/D3 receptors
Pramipexole ER (Mirapex ER)ApprovedSmall moleculeDopamine D2 / D3 receptors

…and 46 more. Research shows the complete landscape.

Research

Unlock the full comparison

Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.

Upcoming events

No upcoming readouts on record for this asset.

All registered studies

Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.

Phase 3 (1)
Early phase / not applicable (1)